Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Lancet 383(9911):3139 Tabernero J et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
He brought them in
Cardiovascular profile evaluations showed comparable levels of heart-related biomarkers, along with inflammatory markers TNF- and IL-6, similar to the positive control
Photograph it held up to a light
Hypoxia and Oxidative Measurements Rat studies examined mitochondrial respiration, antioxidant-gene expression and resistance to experimental hypoxia
As with any emerging pharmacological agent, the establishment of a safe and effective dosage for clinical use necessitates thorough and rigorous clinical trials
.png.jpg)
US$ 28.42
US$ 23.61
US$ 27.48
US$ 22.60
US$ 28.06
US$ 27.56
